Precision oncology: origins, optimism, and potential von Prasad, Vinay, MPH, Fojo, Tito, Prof, Brada, Michael, Prof

Volltext

CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib von Laderian, Bahar, Fojo, Tito

Volltext

Cancer Drugs in the United States: Justum Pretium—The Just Price von KANTARJIAN, Hagop M, FOJO, Tito, MATHISEN, Michael, ZWELLING, Leonard A

Volltext

Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? von Fojo, Tito, Parkinson, David R

Volltext

Precision Oncology: A Strategy we were not Ready to Deploy von Fojo, Tito, MD, PhD

Volltext

Strategies for reversing drug resistance von Fojo, Tito, Bates, Susan

Volltext

Gefitinib and Erlotinib in Metastatic Non‐Small Cell Lung Cancer: A Meta‐Analysis of Toxicity and Efficacy of Randomized Clinical Trials von Burotto, Mauricio, Manasanch, Elisabet E., Wilkerson, Julia, Fojo, Tito

Volltext

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma von Piekarz, Richard L., Frye, Robin, Prince, H. Miles, Kirschbaum, Mark H., Zain, Jasmine, Allen, Steven L., Jaffe, Elaine S., Ling, Alexander, Turner, Maria, Peer, Cody J., Figg, William D., Steinberg, Seth M., Smith, Sonali, Joske, David, Lewis, Ian, Hutchins, Laura, Craig, Michael, Fojo, A. Tito, Wright, John J., Bates, Susan E.

Volltext

The High Cost of Ignorance in Oncology von Fojo, Tito, MD, PhD

Volltext

Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient? von Rixe, Olivier, Fojo, Tito

Volltext

Mechanisms of resistance to PARP inhibitors--three and counting von Fojo, Tito, Bates, Susan

Volltext

Somatic HIF2A Gain-of-Function Mutations in Paraganglioma with Polycythemia von Zhuang, Zhengping, Yang, Chunzhang, Lorenzo, Felipe, Merino, Maria, Fojo, Tito, Kebebew, Electron, Popovic, Vera, Stratakis, Constantine A, Prchal, Josef T, Pacak, Karel

Volltext

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma von PIEKARZ, Richard L, FRYE, Robin, REEDER, Craig, JOSKE, David, FIGG, William D, GARDNER, Erin R, STEINBERG, Seth M, JAFFE, Elaine S, STETLER-STEVENSON, Maryalice, LADE, Stephen, FOJO, A. Tito, BATES, Susan E, TURNER, Maria, WRIGHT, John J, ALLEN, Steven L, KIRSCHBAUM, Mark H, ZAIN, Jasmine, PRINCE, H. Miles, LEONARD, John P, GESKIN, Larisa J

Volltext

Pseudo-progressing to an unmet need von Fojo, Tito, MD, PhD

Volltext

Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma von VEYTSMAN, Irina, NIEMAN, Lynnette, FOJO, Tito

Volltext

Combination Chemotherapy in Advanced Adrenocortical Carcinoma von Fassnacht, Martin, Terzolo, Massimo, Allolio, Bruno, Baudin, Eric, Haak, Harm, Berruti, Alfredo, Welin, Staffan, Schade-Brittinger, Carmen, Lacroix, André, Jarzab, Barbara, Sorbye, Halfdan, Torpy, David J, Stepan, Vinzenz, Schteingart, David E, Arlt, Wiebke, Kroiss, Matthias, Leboulleux, Sophie, Sperone, Paola, Sundin, Anders, Hermsen, Ilse, Hahner, Stefanie, Willenberg, Holger S, Tabarin, Antoine, Quinkler, Marcus, de la Fouchardière, Christelle, Schlumberger, Martin, Mantero, Franco, Weismann, Dirk, Beuschlein, Felix, Gelderblom, Hans, Wilmink, Hanneke, Sender, Monica, Edgerly, Maureen, Kenn, Werner, Fojo, Tito, Müller, Hans-Helge, Skogseid, Britt

Volltext

Waiting for ASCO to “Walk the Walk” von Fojo, Tito

Volltext

Seminars in oncology 50th anniversary von Fojo, Tito

Volltext

MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors von Patel, Dhaval, MD, Boufraqech, Myriem, PhD, Jain, Meenu, PhD, Zhang, Lisa, PhD, He, Mei, MD, Gesuwan, Krisana, CRNP, Gulati, Neelam, BS, Nilubol, Naris, MD, Fojo, Tito, MD, PhD, Kebebew, Electron, MD

Volltext

Moving a Pioneer Journal Into the Future von Fojo, Tito, MD, PhD

Volltext